StemCell Therapy

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced its support of Thyroid Eye Disease (TED) Awareness Week through the launch of new educational resources designed to help people IdentifEYE TED, with a focus on symptoms, risks and where to seek care. In its second year, TED Awareness Week (Nov. 14 - Nov. 20) brings much-needed attention to this serious, progressive and potentially vision-threatening rare autoimmune disease that is often misdiagnosed for more common conditions.1

TED Awareness Week was first established in 2020 through a shared commitment from Horizon Therapeutics and patient advocacy organizations including the Autoimmune Association (formerly American Autoimmune Related Diseases Association, or AARDA), the Alliance for Eye and Vision Research (AEVR), the Graves Disease and Thyroid Foundation (GDATF) and Prevent Blindness. This year, several states including California, Arizona, Massachusetts, New York and Illinois are officially recognizing TED Awareness Week by adopting state resolutions or issuing proclamations. Signaling the growing need for increased public education about this physically and emotionally debilitating disease, state level recognition of TED Awareness Week invites more community involvement and support for people and families affected by TED.

My journey to diagnosis with Thyroid Eye Disease was long and frustrating, as it can be for many people, said Gail S., patient advocate living with TED. I was told my eye symptoms were just part of my Graves disease, but it wasnt until I saw a TED Specialist that I learned it was actually Thyroid Eye Disease. The more we can do to help people quickly recognize the symptoms, the faster they can get help.

For TED Awareness Week 2021, Horizon is launching IdentifEYE TED, an educational campaign designed to help people promptly identify the signs and symptoms of TED. Activities will include:

Weve learned so much from the Thyroid Eye Disease community over the past few years and have become acutely aware of the challenges for people and their families both physical and emotional that come with the condition, said Tim Walbert, chairman, president and chief executive officer, Horizon. Were incredibly proud to continue working with the TED and advocacy communities on this effort to expand Thyroid Eye Disease Awareness Week in its second year to help people recognize Thyroid Eye Disease more quickly, locate a specialist, and get the care they need.

Up to 50% of people living with Graves disease may develop TED; however, TED is a separate disease requiring separate treatment.2,3,4 Symptoms include eye grittiness, redness, swelling and pain, light sensitivity, eye bulging and double vision. 2,3 Symptoms of TED can often be misdiagnosed or confused for other diseases, resulting in delayed diagnosis and treatment. For those with Graves disease or other thyroid conditions, its important to pay close attention to your eyes. At the first sign of any changes, contact a TED Specialist, such as an oculoplastic surgeon or neuro-ophthalmologist. If not treated early, TED can cause serious damage to vision and appearance of the eyes.

To learn more about TED and find a TED Eye Specialist, visit FOCUSonTED.com, and Autoimmune Association (formerly AARDA), AEVR, GDATF and Prevent Blindness for more information.

About Thyroid Eye Disease (TED)TED is a serious, progressive and potentially vision-threatening rare autoimmune disease.1 While TED often occurs in people living with hyperthyroidism or Graves disease, it is a distinct disease that is caused by autoantibodies activating an IGF-1R-mediated signaling complex on cells within the retro-orbital space.5,6 This leads to a cascade of negative effects, which may cause long-term damage to the eyes. As TED progresses, the serious damage it can cause includes proptosis (eye building), strabismus (misalignment of the eyes) and diplopia (double vision) and in some cases, can lead to blindness.7,8 Additional information on TED can be found at ThyroidEyes.com.

About Autoimmune Association (Formerly AARDA)The Autoimmune Association is the worlds leading nonprofit organization dedicated to autoimmune advocacy, awareness, education, and research. Its mission is to lead the fight against autoimmune disease by collaborating to improve healthcare, advance research, and support the community through every step of the journey. For more information, visit http://www.autoimmune.org. Follow on social media: Facebook, Twitter, LinkedIn, Instagram, and YouTube.

About AEVRThe Alliance for Eye and Vision Research (AEVR), a 501(c)3 non-profit foundation, conducts sustained educational efforts about the value of federally funded vision research primarily through its Congressionally recognized Decade of Vision (DOV) 2010-2020 Initiative. Within the DOV, AEVR conducts Congressional Briefings, including a November 19, 2020, virtual global Briefing that recognizes the first annual TED Awareness Week. Visit the Web site at http://www.eyeresearch.org.

About the Graves Disease and Thyroid FoundationThe Graves Disease and Thyroid Foundation (GDATF) is the leading source of help and hope for people with Graves disease and other thyroid related disorders. The organization provides education and support for patients, family members, caregivers, friends and healthcare professionals. GDATF has helped thousands of patients better understand the symptoms and treatment programs for Graves' disease. The Foundation is a 501 C(3) tax-exempt non-profit international charitable organization. For more information, visit http://www.GDATF.org and find us on Twitter (@GDATF), Facebook and Instagram.

About Prevent BlindnessFounded in 1908, Prevent Blindness is the nation's leading volunteer eye health and safety organization dedicated to fighting blindness and saving sight. Focused on promoting a continuum of vision care, Prevent Blindness touches the lives of millions of people each year through public and professional education, advocacy and empowerment, vision screening certification, community and patient service programs, and support for research. These services are made possible through the generous support of the American public. Together with a network of affiliates, Prevent Blindness is committed to eliminating preventable blindness in America. For more information, visit us at preventblindness.org, and follow us on Facebook, Twitter, Instagram, LinkedIn and YouTube.

About HorizonHorizon is focused on the discovery, development and commercialization of medicines that address critical needs for people impacted by rare, autoimmune and severe inflammatory diseases. Our pipeline is purposeful: we apply scientific expertise and courage to bring clinically meaningful therapies to patients. We believe science and compassion must work together to transform lives. For more information on how we go to incredible lengths to impact lives, please visit http://www.horizontherapeutics.com and follow us on Twitter, LinkedIn, Instagram and Facebook.

References

Read more here:
Horizon Therapeutics Recognizes Second Annual Thyroid Eye Disease (TED) Awareness Week with New Educational and Community Building Initiative -...

Research into longevity and healthy aging has progressed rapidly in recent years, but intense interest from the public, corporations, and the media has created an environment in which unfounded claims can be hard to separate from scientific facts.

In February, a group of 16 researchers from Harvard, MIT, and other institutions around the U.S. and Europe launched the nonprofit Academy for Health and Lifespan Research to promote future work, ease collaborations between scientists, and ensure that governments and corporations are making decisions based on the latest facts instead of rumor, speculation, or hype.

The Boston-based organization will form a nexus for work on extending the human health span, fighting the myriad diseases associated with aging, and fostering the work of junior researchers. Harvard Medical School Genetics Professor David Sinclair, one of the new academys founding members and director of the Paul F. Glenn Center for the Biology of Aging at HMS, spoke to the Gazette about the status of aging research and the mission of the academy.

GAZETTE:Tell me about the academy. Is it intended to be mainly an advocacy organization?

SINCLAIR: The academy has been formed because our field of aging and longevity research has reached a point of maturity where the leaders in the field believe that we can have or will have a big impact on the planet. That impact will be in medicine, in health span, and in its knock-on effect on [everything from] human productivity to Social Security.

We wanted to come together to speak with one voice, to be able to help corporations and governments understand what things they should be thinking about now and give realistic projections of what life is going to be like 10, 20, 50 years from now. Because its not a question of if theres going to be an impact, its really a question of what kind of a future we want to build when this happens.

GAZETTE: What kind of impact are we talking about? When you think about 10, 20, 50 years in the future, how do you see aging being transformed in the U.S. and around the world?

SINCLAIR: The 16 researchers in the academy have all been working on this for most, if not all, of our careers. So that spans for many of us over 25 years. When we started, research on aging at the molecular level was the backwater of biology, but in the last 25 years, aging has moved to the forefront of science. Its actually rare to open a leading scientific journal and not see a new breakthrough in our understanding of the aging process.

Recently, weve moved from being able to extend health and lifespan of simple organisms like yeast and worms and flies to being able to do this quite easily in animals, in mice and monkeys. With that knowledge how to keep the body younger and not develop diseases of aging we think its now prime time for having an impact on the globe.

By impact, I mean that instead of tackling one disease at a time, which is the way 20th-century medicine and pharmaceutical development was practiced, we believe we can [develop] medicines that will treat aging at its source and thereby have a much greater impact on health and lifespan than drugs that target a single disease.

Heart disease medicine may keep your heart healthy for an extra five or 10 years, but does nothing for your brain. So, were ending up with a population of people who live longer but not better and who need a lot of help, if theyre not completely [in the grip of] dementia. We dont think thats necessarily the only or the best approach.

Were generally in denial that, for most of the diseases that we get these days, the root cause is aging. I dont know 10-year-olds that get Alzheimers disease or heart disease.

David Sinclair

Now, we have the knowledge. Were developing the technologies to not just delay these diseases of aging but actually reverse aspects of them. Imagine you have a treatment for heart disease, but as a side effect youd also be protected against Alzheimers, cancer, and frailty. Youd live a longer and healthier life.

The reason we can extend the lifespan of animals is not because we can just make them live longer, but we keep them healthy. The animals dont get heart disease, cancer, Alzheimers, until sometimes 20 percent later in their life. And so thats 20 percent longer youth, not just 20 percent longer life.

GAZETTE: Are there regulatory hurdles? When weve spoken in the past, youve mentioned that the FDA considers aging a natural process and therefore wont approve drugs to treat it. Are we at a point where that is becoming a hurdle in getting advances out to the people who need them?

SINCLAIR: Opinions are changing rapidly about whether aging should be a condition that a doctor can prescribe a medicine for. Thats essentially what a disease is. Its something that a doctor can read the label that this medicine is for aging or age-related conditions. Were not at that point yet.

We currently live in a world where aging is so common that its considered by most of the world, including the medical community, as something thats natural and inevitable. And if somethings considered inevitable, typically you dont focus on it in the same way as something you can treat. Cancer was a natural part of life at one time, in the same way that aging is today. A hundred years ago, doctors didnt focus on treating cancer as much as we do now, because then you couldnt do much, if anything, about it. As soon as you show you can modify the disease process, like we learned in the 1970s with the discovery of oncogenes that cause cancer and increasingly so today then theres renewed hope, and views about the condition shift.

There are now dozens of companies working on therapies that could potentially extend overall human health and lifespan, but none of them are working specifically toward an approval for aging because the FDA wouldnt even know where to start. But that may be changing quickly. Ive been part of a group that talked with the FDA, and they are willing and also quite enthusiastic about considering a change that defines aging as a disease. They would like us, first, to show that its possible to change the rate of aging, which in my view is backward, but thats what they want.

In Australia, the government is 100 percent behind this, at the FDA level and in the Ministry for Health. Im hopeful that one country in the world it may be Australia, it may be the U.S., it may be an Asian country will change its definition of aging. Once one country changes its definition, then it will be a domino effect and the others will follow.

One of the biggest changes that happened last year was the World Health Organization, in their international disease codebook, declared aging a condition that is treatable. So now doctors and countries can report back to the World Health Organization how many people in their country are suffering from this condition known as old age.

Were generally in denial that, for most of the diseases that we get these days, the root cause is aging. I dont know 10-year-olds that get Alzheimers disease or heart disease. Its aging that increases the risk 1,000-fold for cancer, while if you smoke, it goes up fivefold. Which is more important to be focused on?

GAZETTE: What excites you most about the state of anti-aging and longevity research?

SINCLAIR: Well, I hate to pick favorite children. Someone will always be upset. I have my hands in a few pies, but the most recent one that Im excited about is cellular reprogramming.

GAZETTE:And how does that occur?

SINCLAIR: We introduce a combination of genes into the animal, or the cell, and we see that the tissue is rejuvenated as though it was young again. So it can heal, it can start new growth, like it was young. And if we can figure out how to deliver that to patients in a safe way, then its quite possible that aging is a reversible disease.

GAZETTE: What genes are we changing?

SINCLAIR: Were using a combination of Yamanaka factors [used to reprogram differentiated adult cells into induced pluripotent stem cells] that are used to make stem cells currently in a dish, but what were finding is that you can introduce them into the animal as well. They tolerate it well and tissues rejuvenate.

I havent published it yet, so I cant say too much, but were writing up the paper now that shows that parts of the mouses body that we thought would not ever improve are able to be regenerated. So were licensing that technology and hoping that it will be tested in the clinic in the next two years.

Read the original:
Longevity and anti-aging research: Prime time for an ...

In the beef cattle industry today, South Devon cattle deliver necessary traits for success. They are an English breed that can outcross with other English and Continental cattle breeds.

Tests and years of selective breeding on five continents show that South Devon cattle are feed efficient, fertile and maternal, with superior carcass traits. They are well-known for their longevity and 100s of years of docility are bred right into their genetics.

These economically important traits combine a uniform approach and balance to commercial and registered ranching and feeding operations with the use of South Devon genetics.

Profit driven cow/calf operations are looking for a level of fertility, low feed intake, high weaning weight production and calf value that South Devon can deliver. In the feedlot, lower feed intake and carcass merit are a compliment of the South Devon breed.

In North America South Devon cattle are primarily polled and can be found in black or red-hided genetics.

Cattle operations using South Devon genetics can increase their profitability with a breed suitable for any North American geographic location.

See the rest here:
North American South Devon Association

The researchers also found that people who drank red wine had a lower body mass index (BMI). This also could be why drinking red wine in moderation is associated with health. Its not that red wine makes you healthier; its that red wine drinkers may be healthier to begin with.

People who drink red wine often also do more exercise and [are] more affluent and healthier, says Bellis.

The same is true of the gut health question: because the study was observational, the researchers couldnt establish whether a single glass of red wine a week makes your gut healthier, or people with healthier guts happened to be the kind to drink a glass a week. And randomised control trials, where participants are split into groups and their health measured as they follow different diets, can be particularly unethical when it involves alcohol.

There have been a few randomised control trials but these have been less than conclusive. A 2016 study found that having one glass of red wine with their evening meal every day for six months didnt affect the blood pressure of people with diabetes.

Another randomised control study from 2015 found that drinking 150ml of red wine (again, the amount held in a champagne flute), can lower the risk of developing stroke and heart disease among people with diabetes.

Healthiest option

In fact, while red wine may be the healthiest drink option, its healthier to abstain entirely, says author of the study looking at wine consumption and gut health, Caroline Le Roy, research associate at the Department of Twins Research at Kings College London.

We know alcohol is bad for us, she says. If you drink, it should be red wine, as this is the only alcoholic drink thats been found to have a beneficial effect, but Im not encouraging people to drink red wine.

Here is the original post:
Can drinking red wine ever be good for us? - BBC Future

image:Schematic illustration of loss of resilience along aging trajectories view more

Credit: GERO PTE. LTD.

The research team of Gero, a Singapore-based biotech company in collaboration with Roswell Park Comprehensive Cancer Center in Buffalo NY, announces a publication in Nature Communications, a journal of Nature portfolio, presenting the results of the study on associations between aging and the loss of the ability to recover from stresses.

Recently, we have witnessed the first promising examples of biological age reversal by experimental interventions. Indeed, many biological clock types properly predict more years of life for those who choose healthy lifestyles or quit unhealthy ones, such as smoking. What has been still unknown is how quickly biological age is changing over time for the same individual. And especially, how one would distinguish between the transient fluctuations and the genuine bioage change trend.

The emergence of big biomedical data involving multiple measurements from the same subjects brings about a whole range of novel opportunities and practical tools to understand and quantify the aging process in humans. A team of experts in biology and biophysics presented results of a detailed analysis of dynamic properties of the fluctuations of physiological indices along individual aging trajectories.

Healthy human subjects turned out to be very resilient, whereas the loss of resilience turned out to be related to chronic diseases and elevated all-cause mortality risks. The rate of recovery to the equilibrium baseline level after stresses was found to deteriorate with age. Accordingly, the time needed to recover was getting longer and longer. Being around 2 weeks for 40 y.o. healthy adults the recovery time stretched to 6 weeks for 80 y.o. on average in the population. This finding was confirmed in two different datasets based on two different kinds of biological measurements - blood test parameters on one hand and physical activity levels recorded by wearable devices on the other hand.

"Calculation of resilience based on physical activity data streams has been implemented in GeroSense iPhone app and made available for the research community via web-based API." - commented the first author of the study, Tim Pyrkov, head of the mHealth project at Gero.

If the trend holds at later ages, the extrapolation shows a complete loss of human body resilience, that is the ability to recover, at some age around 120-150 y.o. The reduced resilience was observed even in individuals not suffering from major chronic disease and led to the increase in the range of the fluctuations of physiological indices. As we age, more and more time is required to recover after a perturbation, and on average we spend less and less time close to the optimal physiological state.

The predicted loss of resilience even in the healthiest, most successfully aging individuals, might explain why we do not see an evidential increase of the maximum lifespan, while the average lifespan was steadily growing during the past decades. The divergent fluctuations of physiological indices may mean that no intervention that does not affect the decline in resilience may effectively increase the maximum lifespan and hence may only lead to an incremental increase in human longevity.

Aging in humans is a complex and multi-stage process. It would, therefore, be difficult to compress the aging process into a single number, such as biological age. Gero's work shows that longitudinal studies open a whole new window on the aging process and produce independent biomarkers of human aging, suitable for applications in geroscience and future clinical trials of anti-aging interventions.

"Aging in humans exhibits universal features common to complex systems operating on the brink of disintegration. This work is a demonstration of how concepts borrowed from physical sciences can be used in biology to probe different aspects of senescence and frailty to produce strong interventions against aging.", - says Peter Fedichev, co-founder and CEO of Gero.

Accordingly, no strong life extension is possible by preventing or curing diseases without interception of the aging process, the root cause of the underlying loss of resilience. We do not foresee any laws of nature prohibiting such an intervention. Therefore, the aging model presented in this work may guide the development of life-extending therapies with the strongest possible effects on healthspan.

"This work by the Gero team shows that longitudinal studies provide novel possibilities for understanding the aging process and systematic identification of biomarkers of human aging in large biomedical data. The research will help to understand the limits of longevity and future anti-aging interventions. What's even more important, the study may help to bridge the rising gap between the health- and life-span, which continues to widen in most developing countries." - says Brian Kennedy, Distinguished Professor of Biochemistry and Physiology at National University Singapore.

"This work, in my opinion, is a conceptual breakthrough because it determines and separates the roles of fundamental factors in human longevity - the aging, defined as progressive loss of resilience, and age-related diseases, as "executors of death" following the loss of resilience. It explains why even most effective prevention and treatment of age-related diseases could only improve the average but not the maximal lifespan unless true antiaging therapies have been developed" - says prof. Andrei Gudkov, PhD, Sr. Vice President and Chair of Department of Cell Stress Biology at Roswell Park Comprehensive Cancer Center, a co-author of this work and a co-founder of Genome Protection, Inc., a biotech company that is focused on the development of antiaging therapies/.

"The investigation shows that recovery rate is an important signature of aging that can guide the development of drugs to slow the process and extend healthspan." - commented David Sinclair, Harvard Medical School professor of genetics.

"The research from Gero surprisingly comes to a similar quantification of human resilience - a proposed biomarker of ageing - based on two very different kinds of data: blood test parameters on one hand and physical activity levels recorded by wearable devices on the other hand. I'm very excited to see how Person-generated Health Data, including data from commercial wearables, can help create individual, longitudinal profiles of health that will be instrumental to shed light on lifetime-scale health phenomena, such as ageing." - commented Luca Foschini, Co-founder & Chief Data Scientist at Evidation Health.

Two aging markers

The authors characterized the dynamics of physiological parameters on time scales of human lifespan by a minimum set of two parameters. The first is an instant value, often referred to as the biological age, and is exemplified in this work by the Dynamic Organism State Index (DOSI). The quantity is associated with stresses, lifestyles and chronic diseases and can be computed from a standard blood test.

The other parameter - the resilience - is new and reflects the dynamic properties of the organism state fluctuations: it informs how quickly the DOSI value gets back to the norm in response to stresses.

When does aging start?

Age-related changes in physiological parameters start from birth. However, various parameters change in different ways at different stages of life, see, e.g., a previous work by the same authors published in Aging US in 2018).

The data from the Nature Communications work shows that there is a good differentiation between the growth phase (mostly complete by the age of 30 and following the universal growth theory by Geoffrey West and aging. At 40+ years, aging manifests itself as a slow (linear, sub-exponential) deviation of physiological indices from their reference values.

How often should one measure biological age?

Physiological parameters are naturally subject to fluctuations around some equilibrium level. Glucose levels rise and drop after having a meal, the number of sleeping hours is slightly different each day. Yet, one can collect a longitudinal dataset, that is a series of such measurements for the same person, and observe that the average levels are different between individuals. Resilience also requires repeated measurements, since one needs to know exactly when recovery was achieved to calculate the resilience.

Importantly, resilience also provides a convenient guide on how often repeated measurements should be taken. As a rule of thumb, the period of observation required for the robust bioage determination should comprise multiple stress and recovery events. For the most healthy individuals such an observation period would amount to several months and should increase with age. During that time, a robust bioage determination would require several data points per recovery time, that is ideally one measurement in a few days.

Wearable technology comes into play

In 2021, the only practical way to achieve a high (once-per-day or better) sampling rate is to use mobile/wearable sensor data.

In another paper, the authors have focused on wearable/mobile sensor data. They have built "wearable DOSI", which they called GeroSense and reported its validation tests in Pyrkov et al. Aging (Albany NY) 13.6 (2021): 7900. GeroSense can be used to compute resilience. Population study shows that the number of individuals showing signs of the loss of resilience increases exponentially with age and doubles every 8 years at a rate matching that of the Gompertz mortality law (the observation by B. Gompertz from 1827, who observed for the first time that the all-cause mortality rate doubles every 8 years).

###

About Gero

Gero is a data-driven biotech company applying modern AI/ML tools to big longitudinal biomedical data to understand aging and major diseases.

Gero AI/ML models are originating from the physics of complex dynamic systems. We have presented our unique approach in Frontiers in Genetics (Fedichev 2018, Frontiers in genetics 9:483). We combine the potential of deep neural networks with the physical models to study human health as a dynamic process. In conjunction with high-quality genetics data, we produce quantitative explanatory models of (aka theory of) aging and complex diseases, as well as actional drug target hypotheses.

Gero conducts high-quality research in collaborations with Harvard Medical School, Massachusetts Institute of Technology, University of Edinburgh, National University of Singapore, Moscow Institute of Physics and Technology, and Roswell Park Comprehensive Cancer Center. The company is a regular contributor to peer-reviewed journals.

Gero has developed a unique framework "GeroSense" for continuous day-to-day monitoring of biological age based on data streams of mobile and wearable sensors. "GeroSense" provides biological age monitoring in our free iPhone app.

Gero encourages using "GeroSense" via web API for monitoring of anti-aging and pro-longevity effects of therapies as well as lifestyle choices, physical activities, diets, food supplements, recommended by health/fitness and wellness apps (see https://techcrunch.com/2021/05/07/longevity-startup-gero-ai-has-a-mobile-api-for-quantifying-health-changes/).

Gero is funded by AI champions, including AIMATTER founders (recently acquired by Google). In 2019 and 2021, Gero was also named one of the leading companies in artificial intelligence in life extension along with Google and IBM.

About Roswell Park Comprehensive Cancer Center

Roswell Park Comprehensive Cancer Center is a community united by the drive to eliminate cancer's grip on humanity by unlocking its secrets through personalized approaches and unleashing the healing power of hope. Founded by Dr. Roswell Park in 1898, it is the only National Cancer Institute-designated comprehensive cancer center in Upstate New York. Learn more at http://www.roswellpark.org, or contact us at 1-800-ROSWELL (1-800-767-9355) or ASKRoswell@RoswellPark.org.

Nature Communications

The rest is here:
Gero scientists found a way to break the limi | EurekAlert!

BOSTON, Nov. 16, 2021 /PRNewswire/ -- Embark Veterinary, Inc., a global leader in dog genetics, today announced that it will be the preferred dog DNA test sponsor of The National Dog Show. Hosted by The Kennel Club of Philadelphia and licensed by the American Kennel Club, the 20th anniversary Thanksgiving Day special will take place at the Greater Philadelphia Expo Center in Oaks, Pa. Nov. 20-21. It will be open to the vaccinated public for the first time since 2019 due to the COVID-19 pandemic.

Embark recently launched the first-ever DNA test for purebred pet owners, leading the dog DNA testing evolution from breed discovery to a personalized pet care necessity. Embark's data shows that 75% of dogs are carriers, or at risk for, a genetic health condition. But, with hundreds of actionable health insights and the most accurate, detailed data on their dog's health, Embark is helping breeders, owners, and veterinarians make proactive choices that address any breed-specific health conditions and traits.

"The National Dog Show Presented by Purina is a Thanksgiving tradition for many families, and we're proud to become a part of that tradition this year," said Embark CEO and Cofounder Ryan Boyko. "One of the silver linings of the pandemic has been the opportunity to better understand, appreciate and bond with our dogs. As families come together to watch The National Dog Show this year, we hope they'll consider learning more about how to improve their dog's health through genetic screening."

Embark aims to extend dogs' lives by three years within the next decade. A key to achieving that goal is building tools that help breeders make better mating pairs that improve the health of their breeding line, offering genetic counseling, and screening for breed-relevant genetic health conditions. Embark salutes the breeders exhibiting at the Kennel Club of Philadelphia dog show and their important work in breed preservation.

"We are looking forward to working with Embark Veterinary in support of the important work that they do for our canine friends, pet parents, and the veterinary community," said Kennel Club of Philadelphia President Wayne Ferguson. "There's great interest in canine genetics and show attendees in Philadelphia will have the opportunity to learn more at the Embark expo booth."

About Embark Embark Veterinary, Inc. was launched in 2015 by two brothers, Adam and Ryan Boyko, who have a passion for scientific research and a lifelong love for dogs. Starting with their best-in-class canine DNA test, Embark is building a powerful platform for scientific discovery that will accelerate advancements in personalized dog care. Embark offers the most scientifically advanced, most trusted, and highest-rated dog DNA tests on the market that helps dog owners, breeders, and veterinarians learn about their dog's breed, health, and ancestry. Customers gain hundreds of actionable insights that inform more proactive care, and every test fuels new research to help all dogs lead longer, healthier lives. Embark is an official research partner of Cornell University College of Veterinary Medicine, was named to the Inc. 5000 list for the past two years, and was included on Forbes' next billion-dollar startups list.

For more information, visit Embark's website at EmbarkVet.com, and follow Embark on Facebook, Twitter, and Instagram.

SOURCE Embark Veterinary Inc.

http://EmbarkVet.com

Read this article:
Embark sponsors The National Dog Show, in commitment to improving life and longevity of all dogs - PRNewswire

Consider 100 baby boys and 100 baby girls born in 1950. Experts predict that 46 of the men and 61 of the women a third more will still be alive at age 80 in 2030.

Even Steven Austad, an expert on aging at the University of Alabama at Birmingham, didnt give statistics like that much thought until about 10 years ago. Everyone knew that women outlived men. He figured it was just because men had more heart disease.

But Austad, who is senior scientific director of the American Federation for Aging Research, is a sucker for topics that others take for granted, and he dug deeper. He learned that girls started out-surviving boys even before they were born and that their survival advantage lasted throughout life. It was present in virtually every country, rich or poor. Women were more likely to live through natural disasters, famines, pandemics (including COVID-19) and many of the diseases that most often kill human beings. Under almost any condition we can imagine, women do better, he said.

A rare upside for men was that those who made it to their senior years were less disabled than female peers. There were also surprising studies that found that a few drugs that extended the life of male mice did nothing for females. Thats a really stunning result, said Richard Miller, a biogerontologist who directs the Paul F. Glenn Center for Aging Research at the University of Michigan and has been studying life-extending drugs in mice. One medication, he said, worked in both sexes.

Austad and a growing cadre of researchers started to think that these differences in aging between men and women were fundamental to human biology and potentially much more complex and divergent than many had assumed. They are now in the early stages of studying how our chromosomes and genes, hormones and immune systems influence how long and how well we live, with an eye toward expanding our healthy lifespans.

If we could find a way to make men live as long as women and make women be as healthy as men later in life, then we would have an enormous impact on our lives, Austad said.

Candace Kerr, a stem cell biologist in the division of aging biology at the National Institute on Aging, agreed that understanding these sex differences could improve the health of both men and women as they aged. It paves the way to finding sex-specific targets for disease, she said.

For decades, scientists assumed that information they gleaned from male patients and male lab animals would naturally apply to females, as well. Since 2016, the National Institutes of Health has required scientists to incorporate males and females into the design, analysis and reporting of clinical research studies of people and vertebrate animals.

Now researchers are finding unexpected differences throughout our bodies, but they say its too soon to draw sweeping conclusions. I think that we are in a renaissance of sorts in really beginning to understand and appreciate the differences, said Dena Dubal, a neurologist at University of California-San Francisco who studies how to slow aging with a focus on hormones and genetics. Her research has found fascinating evidence of the benefits women may derive from their second X chromosome.

The signs that women are the tougher sex when it comes to health are copious. Eighty-five percent to 90% of centenarians are women. All of the worlds 10 oldest people with credible birth records were female, Austad said. In 2018, women died at a lower age-adjusted rate of 13 of the top 15 causes of death, according to the National Center for Health Statistics. There was no sex difference for stroke. Women were more likely to die of Alzheimers disease, although men who get dementia die of it more quickly, said Michelle Mielke, a Mayo Clinic epidemiologist who studies sex differences in neurodegeneration.

Women tend to die of the same basic things that men do, but they die at later ages, Miller said.

At the cellular level, womens brains look four to five years younger than mens, Dubal said. Many biological markers indicate faster aging in almost all of the tissues in male bodies, Kerr said. Women get heart disease later. Their vascular health is generally better than mens, although they have more disease in small blood vessels in late life, Mielke said. Womens immune systems respond more quickly to viral invasions. This is one explanation for why theyre more likely to recover. It may also be why theyre more prone to autoimmune diseases than men.

Then we come to what Austad calls the morbidity-mortality paradox. Men who survive into late middle age and old age tend to have less disability than women. One theory is that men die of diseases that women survive, but the women do not emerge unscathed. Many women will survive and remain fairly functional after diseases that men would have died from, Miller said.

Anne B. Newman, a geriatrician and epidemiologist at the University of Pittsburgh, added that women are more prone to arthritis, which causes disability. Everyone loses muscle mass with age, and women start out with weaker muscles and a higher percentage of body fat. Women are also more prone to osteoporosis after menopause, and that puts them at risk for broken hips. There are more older women with frailty, partly because frail men dont live long.

Women are just physically less endowed to keep moving as they get older, Newman said.

READ MORE: It's never too late to start moving, but you may not catch up to lifelong exercisers

As to why women live longer, the theories are many and complex.

The gap between male and female lifespan widened during the 20th century. Caleb Finch, a biologist at the University of Southern California who studied that phenomenon, thought lung cancer and heart disease accounted for most of the difference. He also studied an indigenous Bolivian population whose pre-industrial lifestyle included exercise and a healthy diet. People there had very little coronary artery disease, but men still had more evidence of blood vessel damage than women.

Newman added that women began living longer when better medical care meant they less often bled to death or became infected during childbirth. She thinks that qualities that allow women to successfully carry a child, such as the ability to tolerate stress and store additional nutrition, may lengthen their lifespans.

You cant ignore behavior. Men are more likely to smoke and eat fatty food. Theyre also less likely to see doctors regularly and get cancer screenings and flu and COVID-19 vaccines. They more often age in isolation. Behavior feels like more than half of the picture, said Aroonsiri Howell, a Temple Health geriatrician.

Young men are prone to risky and potentially deadly activities, a period that Austad calls testosterone dementia. Their death rate compared to womens slows after 35 or so, but its still higher.

Finch said trying to tease out whats affecting our aging is like analyzing a hoard of arrows shot into the air at the same time but traveling at different rates. Genes and hormones matter, but the role of culture and society in shaping the outcomes is also huge and not easy to define at the molecular level.

Beyond behavior, much current research focuses on hormones and sex chromosomes. Women have two X chromosomes, one from their mother and one from their father. Men have an X from their mother and a Y from their father.

Those two Xs give women a richer dose of X-related genes. In each cell of a womans body, one X dominates and the other is mostly inactivated, but its not always the same X. Early in life, the mom and dad Xs may split the work fairly evenly, but, as women age, the fitter X may take on a bigger role, Austad said. Plus, scientists now know that the inactivated X isnt really inactivated. About 15% of its genes are functional.

Austad thinks the Y deserves more attention than scientists are giving it, but its clear that it codes for many fewer genes (55) than the X (900). While the second X may give women a safety net of sorts if one of their Xs is faulty, a mans Y chromosome is not much help when theres a problem with his X. This is why certain X-lined diseases, such as fragile X syndrome, hemophilia A, and Duchenne muscular dystrophy are more common in men.

Dubals work with mice suggests that womens extra X complexity also gives women a longevity advantage. She used a technique that allows researchers to grow the gonads of one sex in the bodies of another, thus exposing them to the other sexs hormones. So, genetically female mice could have testicles and penises and male mice could have ovaries and vaginas. She compared four groups of mice: XX mice with ovaries, XX mice with testicles, XY mice with testicles and XY mice with ovaries. The XX mice lived the longest, regardless of their gonads.

The X accounts for about 5% of our genome, Dubal said, and it is rich in brain-related genes. This may help explain why women are more cognitively resilient. One of her studies found that 19 of those genes were associated with slower cognitive aging in women, but not in men. Three genes, meanwhile, were linked to higher levels in men but not women of misformed tau, a protein seen in the brains of people with Alzheimers.

Women may reap the benefits of the double-dose of X throughout their lives, but theres little doubt that things go downhill from an aging perspective after menopause, so hormones are clearly also a factor. Estrogen, the most important female hormone, drops markedly as a woman enters menopause. Testosterone production also slows in men.

Estrogens are thought to be protective against a variety of diseases, whereas testosterone seem to enhance the risk of disease progression, wrote Brnice Benayoun, a geneticist and cell biologist at the University of Southern Californias Leonard Davis School of Gerontology, in a 2020 paper.

The average woman reaches menopause at 51. Studies show that later menopause is associated with longer life.

Jennifer Garrison, a neuroscientist and chemist at the Buck Institute for Research on Aging, focuses on the impact of ovarian aging in women. Menopause makes a womans body age about 6% faster, she said. It unleashes this negative cascade of health effects, including more heart disease, cognitive decline, and bone weakening. She said the ovaries are involved in important communication channels with the brain that have systemic physical implications.

She would like to do away with menopause entirely. Theres no biological imperative to have it, she said. She thinks menopause should be a choice, not something imposed on you by some out-of-date biology. She realizes that not every woman dreams of extra decades of periods and pregnancy fears. Pregnancy and fertility and menstruation can potentially be uncoupled from having functioning ovaries, she said.

No doubt it will take a while to figure out how to do that, and there is no similar fix available to aging men.

In the meantime, Temples Howell counsels male and female patients differently. She tells the men to worry about heart disease and high-fat diets. Women need to worry about preventing osteoporosis and falls.

READ MORE: Steps to prevent falls as we age

And we all can do the usual things that promote healthier aging: Eat good food, avoid smoking and exercise.

Read the original post:
In most ways, women age better than men and live longer. Scientists are trying to figure out why. - The Philadelphia Inquirer

The inherited metabolic disorders market lies mostly with the Caucasian and African American populations of world, especially in North America, Europe, Australia, and Africa, followed by the minority populations from South Asia and East A.

Globally, IMD affects nearly one in every 2,500 to 5,000 individuals with nearly 300 to 600 new cases found in the U.K., according to Public Health Genetics U.K. The specificity and high risk affinity of IMD varies from disorder to disorder, with some disorders like familial cylomicronemia being closely associated with Caucasians and others like porphyria being recoded largely among African Americans. These metabolic disorders are often controllable with certain lifestyle and diet changes, including Familial Cylomicronemia and Phenylketonuria. But some IMDs are highly dangerous and may affect the survivability of a person, such as Huntingtons or Zellweger syndrome.

Get Brochure of the Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=293

A lot of IMDs arise when the mutated gene responsible is inherited by the natural selection process and a large number of these genes are recessive. This is probably why a large number of these metabolic disorders are rare occurrences, whereas certain other genes are dominant in nature; this makes it difficult for a willing parent to conceive a child as the risk for transferring a gene remains high (e.g. Huntingtons). Familial chylomicronemia occurs when an individual genetically inherits Lipoprotein lipase enzyme mutation. This is a very rare genetic disease at occurrence rate of 1 individual per million with chances of symptoms occurring only in homozygous individuals (receiving mutation genes from both parents) or in other words recessive gene transmission.

Global Inherited Metabolic Disorders Market: Current Market Trends

Nowadays, genetic screening via mass spectrometry and DNA testing of all newborn children are done in nearly all of the developed countries and also some developing countries of the world, including India, China, and Brazil, albeit across a small percentage of the national population. This prepares a parent and the child with the necessary precautions and treatment for increasing the longevity of the concerned newborn. The life expectancy of such a child with all the necessary care and precaution is at par with the average individual.

However among many adult populations and in some children, rare genetic metabolic disorders are abruptly presented and often not accurately diagnosed. In such individuals, abnormal metabolic changes are considered to be a type of genetic mutation in routine diagnosis. Symptoms such as growth failure, precocious puberty and development delay in children below 12, and anemia, neurological disorder, cancer, muscle weakness, rapid hormonal changes, and skin changes in adults, are regarded to probably have a genetic metabolic cause.

Get Table of Content of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=293

Global Inherited Metabolic Disorders Market: Treatment Classifications

The treatment of IMDs is broadly classified into dietary restrictions, dietary supplementation, drugs that inhibit or regulate metabolism, transplantation of the concerned organ, gene therapy, and dialysis in severe cases. In the case of familial cylomicronemia, gene therapy includes Alipogene tiparvovec recombinant gene therapy drug, manufactured by UniQure Inc. This therapy utilizes viruses (adenovirus vector) designed in such a way that upon infection, the gene for producing the lipoprotein lipase is induced into the host cell, thereby producing the enzyme in-vivo. This therapy has shown positive results and is expected to be released into the market soon. For now, the global inherited metabolic disorders Market lies broadly in the dietary supplements market.

Global Inherited Metabolic Disorders Market: Regional Evaluation

The overall estimated global populations of IMD individuals lie in few millions. The niche category of this segment gives little market for specific condition-related products. However, the implications of therapy are huge as some treatments have the potential to completely eradicate these disorders. Several suitable models have been considered for the treatment of hypercholesterolemia and dyslipidemia, which can in turn alter the outcome of cardiovascular diseases to a bare minimum in the future. For now, the inherited metabolic disorders is open for limitless possibilities.

The inherited metabolic disorders lays primarily with the Caucasian and African American populations of world, especially in North America, Europe, Australia, and Africa, followed by the minority populations from South Asia and East Asia.

Get Premium Customized Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=293

Current and Future Threats

Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats.

Accurate Trend Analysis

Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues.

Regional Assessment

Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market.

Industrial Analogy

The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation.

COVID-19 Impact

The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly.

About TMR Research

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

Rohit Bhisey

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

Visit Site: https://www.tmrresearch.com/

Continue reading here:
Inherited Metabolic Disorders Market Study | Know the prominent factors that will help in reshaping the market growth - BioSpace

For a variety of reasons, it takes your body longer to process alcohol as you get older.

Image Credit: AzmanL/E+/GettyImages

The only thing worse than a fun night of cocktails coming to an end is the morning after: when your mouth is as dry as the Sahara, your head feels like it's being used as a bass drum and your insides are churning. You're no stranger to being hungover, but that's the thing why do hangovers now feel so much worse compared to when you were younger?

There's a reason (well, several), and we'll get there but first, a quick brush-up on what causes hangovers:

"There are many different reasons why hangovers occur, and these are due to both the direct actions that alcohol has on the body as well as the way your body metabolizes and gets rid of the alcohol," Heather Moday, MD, Philadelphia-based physician and author of The Immunotype Breakthrough, tells LIVESTRONG.com.

Usually, hangovers happen as a result of drinking excessive amounts of alcohol, but depending on what you drink, combined with your genetics, weight, overall health and even your sex, you can experience hangovers even after consuming small amounts of alcohol.

Because there are so many potential factors at play, the science behind hangovers and the role age can play in their severity is spotty at best but experts do have a few theories as to why your body doesn't react as well to that pitcher of beer anymore.

1. Your Livers Not Functioning as Efficiently

It's the liver's job to metabolize the alcohol we drink, but as we age, its ability to effectively and efficiently get the job done decreases.

"This might be caused by the fact that there's simply less blood flow going to the liver, which means the body takes more time to expel the alcohol," Hisham Korraa, MD, a psychiatry and detox medicine specialist in Newport Beach, California, tells LIVESTRONG.com.

As a result, the alcohol ends up lingering in the body longer and creating a greater blood alcohol concentration than you'd have otherwise.

2. You Have Less Total Body Water

"For the majority of our lives, the percentage of our body weight that's comprised of water is roughly 50 percent," Dr. Korraa says. "However, this starts to decline as we age, due to the overall body composition changes we experience."

We tend to develop more body fat as we age, which contains less water than lean muscle. It hasn't been proven, but some medical experts believe this can lead to there being a higher concentration of alcohol in the bloodstream, which could contribute to worse hangover symptoms.

3. Youre on Medication

Alcohol is broken down by the liver and so are many medications.

"As we get older, we have less liver enzyme activity, so being on medications while also drinking alcohol creates a competition for these enzymes," Seema Bonney, MD, founder and medical director of the Anti-Aging & Longevity Center of Philadelphia, tells LIVESTRONG.com. "This combination may contribute to more significant hangover symptoms."

Consuming alcohol while taking certain medications can also put you at risk of developing more serious health conditions, due to alcohol getting in the way of your medications breaking down properly: Sedatives become more potent, blood pressure meds aren't as effective and blood thinners can increase the risk of serious bleeding, according to the Cleveland Clinic.

4. Youre More Sensitive to the Effects of Alcohol

Odds are, you booze it up less often compared to when you were younger, thanks to an uptick in career, family and social obligations.

"Consuming alcohol less regularly might cause your body to process it slower," Dr. Korraa says. "A reduced alcohol tolerance, combined with a less productive liver, could potentially worsen hangover symptoms in older individuals."

5. Your Hangovers Might Only Seem Worse

"Because you're likely to drink less than you did when you were younger, your memory of past hangovers may be skewed," Dr. Korraa says.

Hangovers of yore may have been just as brutal as the ones you experience now, but because they're not a series regular in your life anymore and you're no longer used to them, you might perceive them as being more catastrophic.

How Long Do Hangovers Last?

The specific combination of symptoms and how severe they are vary from person to person, but hangover symptoms (headaches, dizziness, fatigue, nausea, vomiting, rapid heartbeat, irritability, anxiety and depression) typically peak when the blood alcohol concentration in the body returns to around zero, with the symptoms lasting roughly 24 hours or longer, according to the National Institute on Alcohol Abuse and Alcoholism.

How to Avoid Feeling Hungover

Drinking on an empty stomach is a recipe for hangover city.

Image Credit: skynesher/E+/GettyImages

Unfortunately, the only foolproof way to avoid a hangover is you guessed it not drinking.

"There's no absolute prevention for hangovers if you choose to drink," Dr. Moday says. "However, there are certain things to keep in mind if you do decide to imbibe."

Read on for steps you can take to make hangovers more manageable and maybe even avoidable.

1. Choose Your Drink Wisely

In terms of which alcohols may cause more hangovers, this is somewhat individual. But generally speaking, some people are sensitive to the natural tannins in red wine (chemical compounds derived from the skin, stems and seeds of grapes), as well as the added sulfites (which preserve the freshness of wine and protect it from oxidation), Dr. Moday says.

If your hangovers seem to be especially monstrous after having wine, opt for low-tannin wines like merlot, pinot noir or zinfandel, or varieties that don't contain sulfites.

Prefer liquor or beer? Avoid darker drinks, which tend to contain more congeners chemicals produced during the fermentation process.

"Higher amounts of congeners can be found in drinks like brandy, bourbon and dark ales," Dr. Korraa says. "Lighter drinks, such as gin, vodka and light beers typically have less of this chemical and are thought to be easier for the body to process, lessening the symptoms of a hangover."

2. Dont Drink on an Empty Stomach

If you eat before and while you drink, your body won't absorb the alcohol as quickly as it would on an empty stomach.

"The majority of alcohol is absorbed into the bloodstream through the small intestine," Dr. Korraa says. "If you consume a hearty meal before drinking, the alcohol will stay in your stomach longer, which means it'll be absorbed more slowly and alleviate some of the hangover side effects."

Drinking alcohol faster than your body can process it can overwhelm your system and lead to a worse hangover the next day. Spacing out your drinks might mean the difference between a mild headache and feeling like you've been hit by a bus.

"A healthy liver can process one drink per hour maximum," Dr. Moday says, so consider reading the label on your drink du jour or eyeing the volume of your glass to avoid going overboard.

One drink equals:

4. Alternate Between Booze and Water

When you drink alcohol, you may have noticed that you have to go to the bathroom more than normal.

"Because alcohol's a diuretic, you often end up expelling more liquid than you take in when you're drinking," Dr. Korraa says. Cue dehydration, which increases the odds you'll experience a bad headache, fatigue, weakness and more the following day.

For every alcoholic bevy you have, have a non-alcoholic one to balance the scales. "Doing so will increase your body's water content, which will lower your alcohol concentration," Dr. Bonney says. "It doesn't counter the absorption of alcohol but does slow it down."

5. Get a Jump on Nursing Your Hangover

While there's no guarantee, there are a few steps you can take right after drinking to potentially lessen your chances of a bad hangover the next day.

First up, do your best to finish drinking at least four hours before you go to bed. You might fall asleep faster with alcohol still in your system, but once the alcohol starts to metabolize and the sedative effect wears off, you risk waking up too early and not being able to get back to sleep.

You should also start the process of replenishing your body with fluids. "Be sure to drink a tall glass of water before going to bed," Dr. Korraa says. "You can also drink a sports drink to give your body a boost of electrolytes."

And even if the thought of eating something makes you queasy, it might be a good idea to get something bland in your system to help absorb some of the remaining alcohol in your stomach, Dr. Korraa adds. Try eating at least a plain piece of toast before calling it a night.

You should continue to rehydrate the following day. Tired of plain water? Guzzle some Gatorade or Pedialyte for a one-two punch of H2O and electrolytes.

Do your best to resist any ravenous cravings for greasy foods it's probably your blood sugar talking. Instead, opt for a breakfast that contains protein, carbs and healthy fats to bring your blood sugar back into balance.

"A nutritious breakfast with eggs, spinach, toast, bananas, avocado or oatmeal will be kinder to your stomach and may help reduce your hangover symptoms," Dr. Korraa says.

Lastly, go easy on yourself. Take time out to legitimately rest after your night of debauchery. "There's no cure for a hangover, and you truly just have to let it run its course," Dr. Korraa says. "Be kind to your body and know you'll be back to normal soon."

Link:
Why Hangovers Get Worse as You Age, and What to Do About It - Livestrong

Study also shows beneficial short-term health effects

By ANi

Published: Sat 20 Nov 2021, 6:20 PM

Last updated: Sat 20 Nov 2021, 6:33 PM

Coffee is the most commonly consumed beverage in the world, yet its health effects remain uncertain, says Gregory Marcus, M.D., M.A.S., associate chief of cardiology for research and endowed professor of atrial fibrillation research at the University of California, San Francisco.

While the majority of long-term observational studies have suggested multiple potential benefits of drinking coffee, this is the first randomised trial to investigate the real-time, physiologic consequences of coffee consumption.

A new research has found that caffeinated coffee consumption can have both beneficial and harmful short-term health effects.

The findings were presented at the American Heart Associations Scientific Sessions 2021.

The meeting was fully virtual Saturday from November 13-Monday to November 15, 2021, and was a premier global exchange of the latest scientific advancements, research and evidence-based clinical practice updates in cardiovascular science for health care worldwide.

Marcus and colleagues enrolled 100 adult volunteers, and they were assigned to wear continuously recording ECG devices (to track heart rhythm), wrist-worn devices to track physical activity and sleep; and continuous glucose monitors to track blood sugar levels for two weeks. The participants were an average age of 38 years, 51 per cent were women and 48 per cent were white. Researchers also obtained DNA saliva samples from the participants to assess genetic variants that may affect caffeine metabolism.

ALSO READ:

Participants were then randomly assigned to either avoid or consume coffee for no more than two consecutive days each for 14 consecutive days. Coffee and espresso consumption were recorded in real-time via a timestamp button on the ECG monitor, and researchers tracked trips to coffee shops with geotracking. In addition, participants completed daily questionnaires to detail how much coffee they had consumed every morning.

The analysis found that coffee consumption was associated with a 54 per cent increase in premature ventricular contractions, a type of abnormal heartbeat originating in the lower heart chambers reported to feel like a skipped heartbeat. In contrast, drinking more coffee was associated with fewer episodes of supraventricular tachycardia, an abnormally rapid heart rhythm arising from the upper heart chambers.

Consuming coffee was consistently associated with more physical activity as well as less sleep. Specifically:

- Participants who consumed coffee logged more than 1,000 additional steps per day compared to days when they did not drink coffee.

- On the day participants drank coffee, they had 36 fewer minutes of sleep per night according to their Fitbit devices.

- Drinking more than one coffee drink more than doubled the number of irregular heartbeats arising from the hearts lower chambers.

- Each additional cup of coffee consumed was associated with nearly 600 more steps per day and 18 fewer minutes of sleep per night.

- There were no differences in continuously recorded glucose measured when the study participants consumed versus avoided coffee.

These findings were corroborated by analyses of adherence to their randomization assignment and amplified when more versus less coffee was consumed.

ALSO READ:

More physical activity, which appears to be prompted by coffee consumption, has numerous health benefits, such as reduced risks of Type 2 diabetes and several cancers, and is associated with greater longevity, Marcus said. On the other hand, reduced sleep is associated with a variety of adverse psychiatric, neurologic and cardiovascular outcomes. More frequent abnormal heartbeats from the upper heart chambers influence risk of atrial fibrillation, and more frequent abnormal beats from the lower chambers, or ventricles, increase the risk of heart failure. These results highlight the complex relationship between coffee and health.

The study participants with genetic variants associated with faster caffeine metabolism exhibited more abnormal heartbeats originating in the ventricles, or PVCs when more caffeinated coffee was consumed. The slower an individual metabolises caffeine based on their genetics, the more sleep they lost when they drank caffeinated coffee.

The investigators also sought to determine if changes in exercise or sleep influenced coffees effects on abnormal heart rhythms, and no such association was identified.

Marcus noted that because coffee was randomly assigned to the study participants, cause-and-effect can be inferred. These observations were made during repeated assessments of days when coffee was consumed versus when it was not for each study participant, eliminating concerns regarding differences in individual-level characteristics as an explanation for these results.

Excerpt from:
Addicted to coffee? Heres how it can be harmful to your health - Khaleej Times

Posted: Nov 15, 2021 / 12:24 PM CST / Updated: Nov 15, 2021 / 12:24 PM CST

According to ClevelandClinic.org, over 100 million people suffer from neuropathy. The condition affects people of all ages but the most vulnerable are older Americans.

Dr. Jarrod Bagley, D.C., founder of Corrective Health, joined Studio 512 Co-Host Rosie Newberry to talk about peripheral neuropathy and how he can help.

Dr. Bagley, how are the nerves affected by neuropathy?

Nerves in the body become damaged and send signals to the brain that translate into pain.The body has a peripheral nervous system that sends signals to the brain and the central nervous system. The damage occurs over time. So, it isnt necessarily something that happens overnight. Therefore, the symptoms, such as a prickly feeling, burning, or tingling in the hands or feet, gradually increase over time.

What things trigger neuropathy?

There are several types of neuropathies.One of the most common forms comes from having diabetes and results from not managing the disease properly.For example, a consistent high level of blood sugar.Also, low vitamin levels, chemotherapy, and even alcoholism can contribute to neuropathy.

Can neuropathy be reversed?

The good news is that in most cases it can be reversed with natural, non-invasive treatments. We can reverse the damage if it has not reached 80% nerve loss. Neuropathy, if not treated by a professional, could lead to being confined to a walker or wheelchair and even amputation. It is important to get evaluated sooner than later. Corrective Health uses no drugs, no injections, and no surgeries. In fact, we have the most advanced non-surgical FDA-cleared treatments available that focus on regenerating nerves and arteries.

I understand you have an offer for our viewers.A $49 Neuropathy Special?

Yes, that includes a personal consultation, exam, and report of findings.

$49 Neuropathy Special for the first 25 callers (retail value of $249.00), which includes a personal consultation with a physician, complete exam, report of findings. Call Corrective Health at 512-263-0040.

That is a great offer for folks suffering from neuropathy.

During the exam, we calculate down to the exact percentage of how much sensory loss you have in your hands and feet. Its critical to calculate the sensory loss early because once you have reached a certain point nothing can be done.

Doctor, if someone is suffering from neuropathy, how soon can they be seen?

We have trained staff ready to address the specific needs and treatments of each patient. Give us a call.There is no reason to live in pain.

If you or someone you know suffers from chronic pain or neuropathy, call 512-263-0040. First 25 callers are eligible for the $49 Neuropathy Special. Visit CorrectiveHealthATX.com to learn more.

This segment is paid for by Corrective Health and is intended as an advertisement. Opinions expressed by the guest(s) on this program are solely those of the guest(s) and are not endorsed by this television station.

See the original post:
Find Help For Peripheral Neuropathy With Corrective Health - KXAN.com

PARIS--(BUSINESS WIRE)--France-based biotechnology company AlgoTherapeutix, developer of ATX01, an innovative topical treatment for the pain of peripheral neuropathy, announced today that the ATX01 Phase I trial successfully reached its safety and pharmacokinetics objectives, clearing the way for Phase II development in Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Stphane Thiroloix, Founder & CEO of AlgoTherapeutix, comments : The outcome of this Phase I trial is an important milestone for AlgoTherapeutix. We are delighted that ATX01s innovative approach and formulation did not raise any safety concern, and its PK profile is consistent with our objectives. We are now busy preparing for the pivotal Phase II CIPN study.

Over half of cancer patients treated with chemotherapy - over two million patients in the US and Europe - develop CIPN and experience sensory symptoms and pain in the feet and hands: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. CIPN is a leading cause of modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists and pain specialists.

A recent publication in the Journal of Pain describes the exploratory pharmacological impact of high-dose topical amitriptyline in CIPN patients along with the mechanism of action supporting its activity (https://doi.org/10.1016/j.jpain.2020.11.002)

About AlgoTherapeutix : AlgoTherapeutix is a French biotech founded in 2018 to develop innovative solutions for complex pain. In 2020, AlgoTherapeutix raised a 12 M Series A led by Bpifrance and Omnes Capital to move its lead program ATX01 into clinical development. ATX01 is Phase II ready in painful peripheral neuropathy.

More information on AlgoTherapeutix : http://www.algotx.com

Visit link:
AlgoTherapeutix Completes Phase I for Peripheral Neuropathy Program ATX01, Poised for Phase II Initiation in 2022 - Business Wire

Latest Report on Diabetic Neuropathy Treatment Market size | Industry Segment by Applications (Hospitals , Clinics and Others), by Type (Peripheral Neuropathy , Autonomic Neuropathy , Proximal Neuropathy and Focal Neuropathy), Regional Outlook, Market Demand, Latest Trends, Diabetic Neuropathy Treatment Industry Growth & Revenue by Manufacturers, Company Profiles, Growth Forecasts 2026. Analyzes current market size and upcoming 5 years growth of this industry.

The investors, stakeholders, emerging and established players can leverage the data included in the report to develop impactful growth strategies and improve their position in the current Diabetic Neuropathy Treatment Market landscape. The report provides a thorough assessment of the micro and macro-economic factors that are expected to impact the growth of the Diabetic Neuropathy Treatment Market.

It provides detailed knowledge of upcoming market trends and current conditions in the global market. This report covers the past, present and forecast period for the long-term and collective examination of the Diabetic Neuropathy Treatment market.

Request Sample Copy of this Report @ https://www.nwdiamondnotes.com/request-sample/74964

Pivotal players studied in the Diabetic Neuropathy Treatment Market report:

Propelling Factors & Challenges:

The report provides data associated with the forces influencing the commercialization scale of the global Diabetic Neuropathy Treatment market for and their effect on the revenue graph of this business vertical. The latest trends driving the market along with the challenges this industry is about to experience in the upcoming years are mentioned in the report. The report emphasizes the key driving and restraining forces for this market. The research report sheds light on development factors, business enhancement strategies, statistical growth, financial gain or loss.

By the product type, the market primarily split into:

By the product Applications, the market primarily split into:

Valuable Market Insights Included in the Report

The report addresses the following queries related to the Diabetic Neuropathy Treatment Market

Global Diabetic Neuropathy Treatment Market Pinpoints:

Request Customization on This Report @ https://www.nwdiamondnotes.com/request-for-customization/74964

Follow this link:
Diabetic Neuropathy Treatment Industry Growth Forecast Analysis Manufacturers, Regions, Type and Application to 2026 - Northwest Diamond Notes

Diabetes impacts more than 4.9 million people in the UK, with 90 percent of those cases type two, according to diabetes.org. Though diabetes can be managed, if blood sugar levels are left to spike over long periods of time, it can lead to further conditions.

Long-term blood sugar levels can end up causing severe damage to the nerves.

In particular, nerves that receive signals from your hands and feet can be the most affected.

This is known as diabetic neuropathy, an additional condition that currently has no known cure.

Though around 50 percent of people with diabetes may experience nerve pain at some point in their life, it is not always as severe as diabetic neuropathy.

Most often, it is felt as a "tingling sensation" in the hands and feet, according to Healthline.

READ MORE:Signs of autism in adults - the 8 unique personality traits

"Peripheral neuropathy becomes more likely the longer you have had diabetes.

"Up to one in four people with the condition experience some pain caused by nerve damage."

However, the NHS notes that it can occur for reasons other than diabetes.

The NHS explains: "In some cases, no cause can be identified and this is termed idiopathic neuropathy."

If you have diabetes, your risk for additional side effects are higher if you smoke, drink large amounts of alcohol regularly, or are over the age of 40.

Diabetic neuropathy, though often felt as a tingling feeling, can also feel like numbness.

Fingers, toes, hands and feet are most often affected.

In some cases, burning, sharp or aching pains can be felt in the impacted parts of the body.

Pain may begin mild and grow stronger over time, possibly extending up the arms and legs.

There is no current known cure for the condition.

Instead, the focus of treatment is on maintenance and reducing symptoms worsening.

Options include diet changes, regular exercise and some medications, which can help to reduce blood sugar levels and relieve pain.

Read the original:
Diabetes: The 'tingling' sensation that can be caused by long-term high blood sugar - Daily Express

Nov. 19There's a life-altering infection out there that's plaguing people 65 and older, but it's not the novel coronavirus.

It's shingles, which is recognizable by a painful rash and blisters that scab and pus. While it looks like a skin rash to the naked eye, it's actually an infection to the nerve tissue buried beneath the skin, initiated by the same virus that causes the scourge of most children chickenpox.

"(It's) not a fun thing," said Neosho resident Karol Meyers, who suffered through a round of shingles recently. "(I'm) hoping I don't ever get it again."

Shingles should never be taken lightly or brushed aside, said Dr. Henry Petry, geriatrician with Freeman Center for Geriatric Medicine.

"Almost all of the people who get it have had chickenpox in their lifetime," he said. "The older you are, the more likely you are to get it. Recent (Centers for Disease Control and Prevention) studies state that 1 out of 3 people probably the age of ... 65 or above are probably going to get it."

When shingles first breaks out, "it is very painful," Petry said. The rash mostly centered on the chest or abdomen, but it can also appear on the head or face a few days following the onset of pain "can blister, and it's usually linear, meaning it goes from the back (of the body or head) to the front."

During that time, people will feel varying degrees of pain, which can flare up anywhere on the body where there are nerves. When shingles "gets back (in the nerves) it's like an infection in that area, and it kind of inactivates it and makes it do funny things it's not supposed to do," he said.

When treated, an episode can last between seven and 10 days. If untreated, "there's the possibility of developing a type of neuropathy," which is damage or dysfunction of one or more nerves that result in sporadic pain, numbness, tingling and muscle weakness for years on end, Petry said.

Story continues

"I've had a couple of (patients) who had it, but they didn't get (shingles) around the chest but down their leg, and they developed permanent foot drop from the changes to the sciatic nerve," he said. Petry also said that should the rash appear on the face and blisters form in the eye, it can cause blindness.

These long-term complications of pain and dysfunction "can be very devastating to the quality of life of that person if it's not treated," he said. "The older you are, the more likely you'll have a problem with it."

While it's impossible for two people who previously had chickenpox to pass shingles to one another, it is possible for someone with shingles to pass it to someone who has never previously had chickenpox, he said.

To that end, CDC officials have noticed a slight increase in shingles cases over the past 24 months, most likely due to stresses brought on by COVID-19.

"Stress is a big immune system depressant," Petry said. "Any time that you have a change in your immune system ... that suppresses it, it's down; I don't mean depressed, but you're down" physically. Major stresses, and some back-to-back-to-back stressors lasting for years, "can make your immune system more susceptible to everything, even to the common cold."

There are ways to lessen the risks from shingles. There are three different types of antiviral drugs that work effectively to rid the body of the infection; steroids also help to reduce some of the post-shingles neuropathy symptoms.

But the best and safest way to protect oneself from shingles is to get immunized against it. CDC officials recommend that healthy adults 50 and older get the two-dose vaccine Shingrix. The vaccine, which two years ago replaced a single-dose vaccine, is more than 90% effective at preventing shingles.

Vaccination against shingles "is the one thing that we really, really recommend as you get older ... in order to prevent the spread of it so it can't be a life-altering infection," Petry said.

Kevin McClintock is features editor for The Joplin Globe.

Follow this link:
Vaccinations urged against shingles, a viral infection that's on the rise - Yahoo News

Highlights

Events and Activities

NIBGE Email

Welcome to NIBGE

PAEC has clear mandates on the safe use of modern sciences with an aim to improve the socio economic growth of the country. NIBGE is one of the main biotechnology institutes of the four bioscience centers of PAEC and was formally inaugurated by the President of Pakistan in 1994. It is also an affiliate center of ICGEB. The institute is a focal point of modern biotechnology and provides a technology receiving unit to help the development of country through applications of modern biotechnology and genetic engineering. The research programs at NIBGE are mainly aimed at improving agriculture, health, environment and industry and are supported by national and international financial grants. The institute research facilities include state of the art equipments supported by technical services, IT facility and a National Library for Biological Sciences. The institute now offers several services and marketable products. The educational programs leading to MPhil and PhD degrees have also been incorporated in the institutes mandate for the development of human resources in modern sciences.

Announcement

Interview Schedule of M.Phil (Biotechnology)

Featured News

Read more here:
Home :: National Institute for Biotechnology and Genetic ...

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that investigators presented results from the neratinib arm of the Phase II Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT Trial) at the 2021 Society for Neuro-Oncology Annual Meeting. The presentation, entitled Preliminary results of the neratinib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): a phase II platform trial using Bayesian adaptive randomization, was presented as an oral presentation in the Abstract Session: Clinical Trials II Session. A copy of the presentation is available on the Puma Biotechnology website.

The INSIGhT trial is a multisite investigator-initiated Phase II screening adaptive platform trial where patients with newly diagnosed unmethylated glioblastoma who are IDH R132H mutation negative and with genomic data available for biomarker grouping are eligible. All patients receive radiation therapy and temozolomide and then patients are randomized to receive either adjuvant temozolomide or adjuvant treatment with an experimental agent (neratinib). At the initiation of INSIGhT, three experimental arms, each with a proposed genomic biomarker, are tested simultaneously. Initial randomization is equal across arms. As the trial progresses, randomization probabilities adapt on the basis of accumulating results using Bayesian estimation of the biomarker-specific probability of treatment impact on progression-free survival. Treatment arms were allowed to drop because of low probability of treatment impact on overall survival. The primary endpoint of INSIGhT is overall survival (OS). Progression-free survival (PFS) analysis is used to influence randomization. For the neratinib arm of the trial, patients received 240 mg of neratinib daily as a single agent with mandatory loperamide prophylaxis.

For the neratinib arm of the trial, there were 149 patients in the intent-to-treat population, including 81 patients treated with neratinib and 68 patients in the control arm. For the intent-to-treat population, PFS was not significantly longer (HR 0.75; p=0.12, log rank test) with neratinib (median 6.0 months) versus the control arm (median 4.7 months) and there was no significant improvement in OS (HR 1.01; p=0.75) between neratinib (median 13.8 months) vs. the control arm (median 14.7 months). For patients with activation of the EGFR pathway, defined as patients with either EGFR amplification or mutation, PFS was significantly longer (HR 0.58; p=0.04, log rank test) with neratinib (median 6.3 months) vs. the control arm (median 4.6 months); however, there was no significant improvement in overall survival (HR 0.97; p= 0.94) between neratinib (median 14.4 months) vs. the control arm (median 15.3 months).

Neratinib was generally well tolerated in the trial and toxicities for neratinib were similar to that previously described. For the 81 patients treated with neratinib, there were 6 cases (7.4%) of grade 3 diarrhea and no cases of grade 4 diarrhea. No new toxicity signals were identified in the trial.

Isabel Arrillaga-Romany, MD, PhD, Director of Neuro-Oncology Clinical Trials at Mass General Cancer Center, an investigator on the trial who presented the data at SNO, said, Although preliminary results did not achieve the primary endpoint, subgroup analyses demonstrated improved PFS in patients with EGFR activation and a non-significant trend toward improved overall survival in patients with EGFRVIII mutations, which could warrant further investigation. Additionally, we are very pleased that this trial reinforced feasibility of randomized Bayesian adaptive platform trials for newly diagnosed glioblastoma.

Alan H. Auerbach, Chief Executive Officer and President of Puma, added, We would like to thank the INSIGHT trial investigators and the patients for their participation in the trial. This is the first data demonstrating an effect of neratinib in EGFR amplified or mutated glioblastoma. While we are not looking to pursue further clinical investigations of neratinib in this indication, we are evaluating the potential to develop a backup compound HKI-357, which has preclinically demonstrated better EGFR activity, in this indication.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Lactation: Advise women not to breastfeed.

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Pumas business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

Originally posted here:
Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT Trial at the 2021 SNO Annual Meeting - Business Wire

BOSTON--(BUSINESS WIRE)-- GRO Biosciences Inc. (GRObio), an emerging biotechnology company leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics, today announced the hiring of veteran industry executive, Edward Tad Stewart, who joins the team as Chief Business Officer (CBO).

Mr. Stewart has worked extensively in business and corporate development in the biotechnology and pharmaceutical space for more than 20 years. He has played an integral strategic role in scaling platform biotechnology companies from early stages through FDA-approval and product launch. Mr. Stewart served most recently as Chief Business Officer of Ribon Therapeutics. Prior to his role at Ribon he served as President and CEO of Commense, Inc., Chief Business Officer of Crescendo Biologics, and spent many years with Merrimack Pharmaceuticals in various roles, including SVP of Business Development and Head of Commercial. Mr. Stewart received his MBA from Cornell University.

We are thrilled to have Tad join our executive team. His deep experience in business development and transactions will be instrumental to our partnering activities, and his expertise in product development will accelerate our commercialization efforts, said Daniel J. Mandell, PhD, Co-Founder and Chief Executive Officer of GRO Biosciences. Tad is an established leader in biotechnology, and his unique combination of transactional and strategic savvy will be a great asset to GRObio as we continue to advance our platform and pipeline.

About GRO Biosciences

GRO Biosciences (GRObio) is leveraging groundbreaking science to expand the amino acid alphabet and deliver on the promise of protein therapeutics. The Company is transforming treatments for increasingly prevalent chronic medical conditions including autoimmune and metabolic diseases to improve the lives of patients. GRObio is applying its platform to advance partnered and collaborative programs, as well as its own pipeline of protein therapeutics bearing unique NSAA (non-standard amino acid) chemistries. The Companys NSAA therapeutics feature previously unattainable capabilities including unprecedented duration of action and precise regulation of the immune system. GRObio, co-founded by George Church, PhD of Harvard Medical School in 2016, is headquartered in Cambridge, MA. Find GRObio on LinkedIn, Twitter, Instagram, Facebook and the web at grobio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211116005427/en/

Read more from the original source:
GRO Biosciences Strengthens Management Team With Appointment of Veteran Biotechnology Executive, Edward Stewart as Chief Business Officer - BioSpace

Polymerase Chain Reaction (PCR) Sales to Surpass US$ 12 Bn through 2031 as Adoption of Real-Time PCR Surges amid COVID-19

Fact.MRs latest study discusses factors affecting the polymerase chain reaction (PCR) market growth. It provides in-depth analysis of various market segments, including product and end user across seven major regions. The report further profiles leading PCR manufacturers and examines the effect of their growth strategies on the global market.

Fact.MR A Market Research and Competitive Intelligence Provider: According to the latest Fact.MR analysis, the global polymerase chain reaction (PCR) market will reach US$ 3.6 Bn by the end of 2021. Owing to the surging demand for PCR products, the overall market is projected to register growth at 10% CAGR between 2021 and 2031.

Sales in the PCR market are expected to increase with rising prevalence of target diseases and genetic disorders. Also, factors such as growing popularity of portable PCR testing kits, advancements in PCR technology, and increasing government funding for research activities will facilitate the growth in the market.

PCR has emerged as an ideal technique for the amplification of DNA sequences. It is a simple and cost-effective technique which produces results rapidly. It is an extensively used technique in medical laboratory research for a wide range of applications including biomedical research and criminal forensics.

The unprecedented outbreak of COVID-19 had a positive impact on the PCR market. It created huge demand for reliable and rapid detection techniques such as RT-PCR. Various companies also launched novel PCR test kits for the detection of virus.

Also, RT-PCR emerged as an ideal technique for detection of COVID-19 virus. It is significantly faster and has lower risk of contamination or errors.

Request a report sample to gain compressive insights at

https://www.factmr.com/connectus/sample?flag=S&rep_id=4861

As per Fact.MR analysis, PCR reagents will account for around 60% of total PCR market revenue by 2031. Rising demand for diagnostic tests and launch of new reagents specific to the test type are some key factors accelerating the demand for reagents used in polymerase chain reaction. Furthermore, RT PCR systems market to witness significant growth.

Regionally, North America will continue to dominate the PCR market, owing to the presence of a well-established healthcare infrastructure, continuous advances in clinical research, and high prevalence of genetic disorders such as Klinefelter's syndrome and Down syndrome. The region is poised to expand at a healthy growth rate of 7.5% annually.

However, Asia is projected to register the fastest growth on the back of increasing penetration of PCR products, rising government support, high prevalence of chronic diseases, and expanding healthcare infrastructure.

As the demand for PCR continues to rise, leading manufacturers are moving towards developing portable micro-scale devices. They also are introducing advanced PCR instruments, reagents and consumable that will allow quick nucleic acid amplification. This is expected to create growth opportunities for the market, says a Fact.MR analyst

Key Takeaways from Polymerase Chain Reaction Market Survey

Key Drivers

Key Restraints

To gain in-depth insights on Polymerase Chain Reaction Market, request methodology at

https://www.factmr.com/connectus/sample?flag=RM&rep_id=4861

Competitive Landscape

Key players operating in the polymerase chain reaction market are embracing advanced technologies for the development of new products. They have adopted various strategies such as mergers, partnerships, collaborations and manufacturing of advanced portable PCR products to increase their sales.

Some of the prominent players operating in the polymerase chain reaction market profiled by Fact.MR are:

More Insights on the Global Polymerase Chain Reaction Sales Outlook

Fact.MR provides an incisive coverage on global polymerase chain reaction market, presenting historical demand data (2016-2020) and forecast statistics for the period from 2021-2031. The study divulges compelling insights on the global demand for polymerase chain reaction with a detailed segmentation on the basis of:

Key Questions Covered in the Polymerase Chain Reaction Market Outlook Report

Explore Fact.MRs Coverage on the Healthcare Domain

Rapid Medical Diagnostic Kits Market- Infectious disease incidence has been steadily increasing over the last few decades, driving up demand for rapid medical diagnostic kits around the world. The need to detect novel pathogens that cause diseases is propelling the market forward. The low cost of rapid medical diagnostic kits is propelling market growth. Blood glucose testing is in high demand, and it has been growing at the quickest rate of all types of tests across all geographies. Technology advancements and strategic alliances by key market players have paved the way for rapid medical diagnostic kit innovations.

COVID-19 Saliva-based Detection Kits- COVID-19 detection treatments are likely to be in high demand due to the availability of COVID-19 virus variants and the continued danger of infection. Manufacturers are focusing on delivering cost-effective and convenient testing solutions as COVID-19 diagnostics become more widely employed. While vaccination initiatives have reduced the incidence rate in some nations, the virus continues to represent a serious concern and has a high occurrence rate due to mutant forms. Future viral mutant strains, as well as increased knowledge of COVID-19 testing, are predicted to maintain market growth.

PCR and Real-time PCR Molecular Diagnostics Market - The COVID-19 pandemic has boosted prospects for the growth of the PCR and real-time PCR molecular diagnostics market. Real-time (qPCR) and digital (dPCR) PCR tests have been used in a variety of healthcare settings to detect and diagnose potential cases. Because of its high sensitivity, healthcare providers have embraced PCR tests on a large scale. As a result of such trends, the global PCR and real-time PCR molecular diagnostics market is poised to soar to new heights, surpassing a significant revenue threshold in the coming decade.

About Fact.MR

Fact.MR is a market research and consulting agency with deep expertise in emerging market intelligence. Spanning a wide range from automotive & industry 4.0 to healthcare, technology to even the most niche categories. 80% of Fortune 1000's trust us in critical decision making.

MarketNgage is powered by Fact.MR our Unified Intelligence Engine, a revolutionary Market Research Subscription platform with a flexible pricing to suit your needs.

You can access all our healthcare research reports by signing up with MarketNgagesMarket Research Subscriptionwith FREE credits. MarketNgage is powered by Fact.MR A Fully integrated research solution for seamless single-window access Widest coverage on emerging markets, nascent products, and disruptive technologies.

Contact:

Mahendra SinghUS Sales Office11140 Rockville PikeSuite 400Rockville, MD 20852United StatesTel: +1 (628) 251-1583E: sales@factmr.com

Source: Fact.MR

Continue reading here:
Polymerase Chain Reaction (PCR) Market to Expand by 3.3x as Application in Pharmaceutical & Biotechnology Industry Grows - BioSpace

Northampton, MA --News Direct-- Illumina

Were honored to be named to the prestigious 2021 Dow Jones Sustainability Indices for a third year in a row. Illumina received the highest score in the Pharmaceuticals, Biotechnology and Life Sciences industry.

Inclusion in the DJSI highlights our commitment to continuously improving and growing our Corporate Social Responsibility (CSR) program to build a more sustainable and equitable future for all. Our program focuses on accelerating access to genomics, supporting our communities, and integrating environmental stewardship into our operations.

If you would like to hear more about our CSR program, join us at our inaugural ESG Investor event on Tuesday Nov 16 at 11 am PT.

Thank you to all our employees for championing the needs of patients, customers, our communities, and our planet.

View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com

View source version on newsdirect.com: https://newsdirect.com/news/illumina-named-to-2021-dow-jones-sustainability-indices-with-highest-score-in-pharmaceuticals-biotechnology-and-life-sciences-industry-107725996

Excerpt from:
Illumina Named to 2021 Dow Jones Sustainability Indices With Highest Score in Pharmaceuticals, Biotechnology and Life Sciences Industry - Yahoo...